Dihexa: Hype vs. Evidence
Dihexa carries one of the most arresting claims attached to any research peptide, and that claim has done more to shape its reputation than anything in the actual literature. It is worth separating the two, because the gap is wide and the direction of the gap is not obvious.
What It Is
Dihexa is a synthetic hexapeptide derivative, formally N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, developed as an analogue of angiotensin IV.
Angiotensin IV is a fragment of the angiotensin system, and interest in it arose from observations that it influenced cognitive performance in animal models, which was unexpected for a peptide associated primarily with blood pressure regulation. Dihexa was engineered from that lead with two goals: greater metabolic stability, and enough lipophilicity to cross the blood-brain barrier.
The compound is available as Dihexa 10mg.
The Claim That Drives the Interest
The figure that circulates is that dihexa is seven orders of magnitude more potent than BDNF at promoting synaptogenesis. Ten million times.
That number is not invented. It traces to work from Joseph Harding and John Wright’s group at Washington State University, and it refers to a specific in vitro comparison of concentrations required to produce a measured increase in dendritic spine density in cultured hippocampal neurons.
Three qualifications matter, and they are usually dropped when the number is repeated.
It is a potency comparison, not an efficacy comparison. Potency is the concentration needed to produce an effect. Efficacy is the size of the maximum effect. A compound can be enormously more potent and produce a smaller ceiling.
It is in vitro, in cultured neurons, with the compound applied directly. BDNF is a large protein that crosses the blood-brain barrier poorly, so a comparison in a dish is not a comparison of what either does when administered.
And it is a single endpoint, spine density, which is a structural proxy rather than a functional outcome.
The Proposed Mechanism
Dihexa is understood to act on hepatocyte growth factor and its receptor c-Met, rather than on the angiotensin receptors its parent compound targets.
HGF/c-Met signalling is involved in neuronal growth, survival and synapse formation, and the proposal is that dihexa potentiates this axis. Animal work from the originating group reported improvements in task performance in models of cognitive impairment, and this is the strongest part of the evidence base.
It is also where the most serious open question sits, which is covered below.
What Is Missing
The list is short and significant.
There are no published human clinical trials. Not none that are positive, none at all.
There is no published human pharmacokinetic data. Absorption, distribution, half-life and clearance in humans are unknown, including by what route and in what quantity it reaches the central nervous system.
There is no published human safety data, no dose-ranging work and no chronic exposure data in any species at the level a regulatory file would require.
For a compound this widely discussed, that is an unusually empty file. The contrast with the nootropic peptides that do have substantial clinical literature is sharp: Semax has decades of Russian clinical use behind it, and Cerebrolysin has been studied in registered trials in multiple countries. Whatever one makes of those literatures, they exist. P21 sits closer to dihexa, with preclinical support and little else.
The Risk the Hype Skips
The c-Met pathway is not a neutral target.
HGF/c-Met is one of the better characterised oncogenic signalling axes in human biology. Aberrant c-Met activation is implicated in a range of cancers, and a substantial drug development effort has gone into inhibiting it rather than potentiating it.
A compound whose proposed mechanism is potentiation of that axis, with no chronic exposure data in any species, carries a theoretical proliferation risk that is not addressed anywhere in the available literature. This is not a claim that dihexa is carcinogenic. It is a claim that the question has not been asked in print, and that it is the obvious question to ask of this mechanism.
Anyone weighing the seven-orders-of-magnitude figure should weigh this alongside it, because they come from the same body of work.
Why the Angiotensin Origin Still Matters
Dihexa is usually discussed as though its angiotensin heritage were irrelevant, a historical starting point that the engineered compound left behind. That is probably too clean.
The parent system is central to blood pressure regulation, fluid balance and renal function. Dihexa’s proposed primary target is HGF/c-Met rather than the angiotensin receptors, but selectivity claims for a small engineered peptide are rarely absolute, and the published characterisation of what else it binds is thin.
What that means in practice is that cardiovascular and renal effects are not ruled out by the mechanism having been redirected. They are simply unmeasured. For a compound with no human pharmacokinetic data, an unexamined off-target profile on the system it was derived from is a real gap rather than a pedantic one.
Handling Notes
Dihexa’s lipophilicity, the property engineered into it, makes it less soluble in water than most peptides in the catalogue. Protocols for it frequently specify a co-solvent, and the supplier’s reconstitution guidance is the relevant reference rather than the default assumption. General mechanics are in the reconstitution and storage guide.
Because the compound is less commonly produced than the main catalogue items, lot-level documentation is worth more scrutiny here than usual. Identity confirmation by mass spectrometry is the line to check, since a modified hexapeptide offers more opportunities for synthesis error than a simple linear sequence. Reading that paperwork is covered in How to Read a Peptide COA.
The Honest Assessment
Dihexa has a real and interesting preclinical result behind it, an engineered design that addresses a genuine problem with its parent compound, and one of the most quoted and least understood potency figures in the field.
It also has no human data of any kind, and a mechanism with an unexamined theoretical risk attached. That combination puts it firmly in the early research category rather than the emerging-tool category where it is often placed. Further questions on the peptides catalogue are answered in the FAQ.
All products available through Northern Peptides are sold strictly for research purposes only. Nothing in this article constitutes medical advice, and no compound referenced here is approved by Health Canada for human therapeutic use. Researchers are responsible for ensuring their use of any compound complies with applicable laws and institutional guidelines.
